Tags

Type your tag names separated by a space and hit enter

Prognosis following endoscopic injection sclerotherapy for esophageal varices in adults: 20-year follow-up study.
Scand J Gastroenterol. 2008; 43(10):1269-74.SJ

Abstract

OBJECTIVE

Endoscopic injection sclerotherapy (EIS) is beneficial in the management of active hemorrhaging and prevention of recurrent bleeding from esophageal varices. However, its long-term efficacy and safety are poorly defined. The aim of this study was to determine long-term cumulative survival and clarify negative predictive factors for survival following EIS in patients with esophageal varices.

MATERIAL AND METHODS

Between 1981 and 1987, 72 patients were prospectively enrolled in a post-EIS follow-up program. Variceal rebleeding, recurrence, and survival were recorded in follow-up examinations conducted for up to 20 years.

RESULTS

The mean follow-up period was 86.9 months. The cumulative survival rates were 65.2%, 53.6%, 26.1%, and 11.6% at 36, 60, 120, and 240 months, respectively, with liver failure the most common cause of death. Esophageal varices were eradicated in 93.1% of the patients following EIS and no recurrence of varices was seen beyond 7 years. Significant negative predictive factors for survival rate shown by Cox's proportional multivariate hazard model analysis were older age, advanced liver damage, presence of hepatocellular carcinoma, and occurrence of rebleeding.

CONCLUSIONS

Long-term survival, rebleeding, and recurrence rates following EIS were clarified. Furthermore, our results clearly demonstrate negative predictive factors for survival after EIS.

Authors+Show Affiliations

Department of Internal Medicine, Izumo City General Medical Center, Shimane, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

18609148

Citation

Yuki, Mika, et al. "Prognosis Following Endoscopic Injection Sclerotherapy for Esophageal Varices in Adults: 20-year Follow-up Study." Scandinavian Journal of Gastroenterology, vol. 43, no. 10, 2008, pp. 1269-74.
Yuki M, Kazumori H, Yamamoto S, et al. Prognosis following endoscopic injection sclerotherapy for esophageal varices in adults: 20-year follow-up study. Scand J Gastroenterol. 2008;43(10):1269-74.
Yuki, M., Kazumori, H., Yamamoto, S., Shizuku, T., & Kinoshita, Y. (2008). Prognosis following endoscopic injection sclerotherapy for esophageal varices in adults: 20-year follow-up study. Scandinavian Journal of Gastroenterology, 43(10), 1269-74. https://doi.org/10.1080/00365520802130217
Yuki M, et al. Prognosis Following Endoscopic Injection Sclerotherapy for Esophageal Varices in Adults: 20-year Follow-up Study. Scand J Gastroenterol. 2008;43(10):1269-74. PubMed PMID: 18609148.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognosis following endoscopic injection sclerotherapy for esophageal varices in adults: 20-year follow-up study. AU - Yuki,Mika, AU - Kazumori,Hideaki, AU - Yamamoto,Shyun, AU - Shizuku,Toshihiro, AU - Kinoshita,Yoshikazu, PY - 2008/7/9/pubmed PY - 2009/2/7/medline PY - 2008/7/9/entrez SP - 1269 EP - 74 JF - Scandinavian journal of gastroenterology JO - Scand J Gastroenterol VL - 43 IS - 10 N2 - OBJECTIVE: Endoscopic injection sclerotherapy (EIS) is beneficial in the management of active hemorrhaging and prevention of recurrent bleeding from esophageal varices. However, its long-term efficacy and safety are poorly defined. The aim of this study was to determine long-term cumulative survival and clarify negative predictive factors for survival following EIS in patients with esophageal varices. MATERIAL AND METHODS: Between 1981 and 1987, 72 patients were prospectively enrolled in a post-EIS follow-up program. Variceal rebleeding, recurrence, and survival were recorded in follow-up examinations conducted for up to 20 years. RESULTS: The mean follow-up period was 86.9 months. The cumulative survival rates were 65.2%, 53.6%, 26.1%, and 11.6% at 36, 60, 120, and 240 months, respectively, with liver failure the most common cause of death. Esophageal varices were eradicated in 93.1% of the patients following EIS and no recurrence of varices was seen beyond 7 years. Significant negative predictive factors for survival rate shown by Cox's proportional multivariate hazard model analysis were older age, advanced liver damage, presence of hepatocellular carcinoma, and occurrence of rebleeding. CONCLUSIONS: Long-term survival, rebleeding, and recurrence rates following EIS were clarified. Furthermore, our results clearly demonstrate negative predictive factors for survival after EIS. SN - 1502-7708 UR - https://www.unboundmedicine.com/medline/citation/18609148/Prognosis_following_endoscopic_injection_sclerotherapy_for_esophageal_varices_in_adults:_20_year_follow_up_study_ L2 - https://www.tandfonline.com/doi/full/10.1080/00365520802130217 DB - PRIME DP - Unbound Medicine ER -